MARKET

CRIS

CRIS

Curis
NASDAQ
0.7000
-0.0377
-5.11%
After Hours: 0.7178 +0.0178 +2.54% 19:51 09/30 EDT
OPEN
0.7377
PREV CLOSE
0.7377
HIGH
0.7551
LOW
0.7000
VOLUME
438.08K
TURNOVER
0
52 WEEK HIGH
8.20
52 WEEK LOW
0.6800
MARKET CAP
64.27M
P/E (TTM)
-1.1309
1D
5D
1M
3M
1Y
5Y
Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket
Gainers
Benzinga · 5d ago
Curis to Present at Upcoming Healthcare Conferences in September
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright 2...
PR Newswire · 09/07 12:00
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/30 22:07
Curis leukemia study's monotherapy part gets FDA nod to resume enrollment, others still under partial hold
Curis (NASDAQ:CRIS) <a href="https://seekingalpha.com/pr/18920633-fda-allow...
Seekingalpha · 08/30 13:00
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.
Benzinga · 08/30 12:52
BBBY, EDU and CRIS among pre market gainers
Mobile Global Esports (MGAM) +40%. IN8bio (INAB) +20%<...
Seekingalpha · 08/30 12:24
BRIEF-Curis Says FDA Allows Patient Enrollment To Resume In Leukemia Study
BRIEF-Curis Says FDA Allows Patient Enrollment To Resume In Leukemia Study
Reuters · 08/30 12:24
Curis Announces FDA Has Notified Co. It May Resume Enrollment Of Additional Patients In Monotherapy Dose Escalation Of Emavusertib In TakeAim Leukemia Study
LEXINGTON, Mass., Aug. 30, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that
Benzinga · 08/30 12:13
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.